VisionCare, Avinger land big VC rounds

Saints Capital has led VisionCare Ophthalmic Technologies to an impressive $31 million round of Series E financing. VisionCare, based in California, is developing visual prosthetic devices for patients with end-stage age-related macular degeneration (AMD). The device, which VisionCare describes as "smaller than a pea," is implanted in an outpatient procedure. New investors are Giza Ventures, General iFinancial Holdings and BSI SA, and current investors include Pitango Venture Capital, Three Arch Partners, ONSET Ventures and Newbury Acquisitions Fund/Infinity CSVC Management also participated.

The capital will be used to launch the CentraSight telescope prosthesis by developing VisionCare's sales and marketing department for the United States, with other markets to follow. The company is also investing in R&D for new visual prosthetic devices for severe retinal disorders.

- here's VisionCare's release

ALSO: Avinger has completed a $25M Series B round of funding which will be used to support commercialization of the company's Wildcat and Kittycat guide wire support catheters. Avinger will also complete development therapeutic catheters which integrate real-time visualization of arterial blockages based on optical coherence tomography imaging technology. Release

Suggested Articles

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.

Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise.